Alvotech (ICE:ALVO)

Market Cap	319.15B
Revenue (ttm)	67.99B
Net Income (ttm)	-32.04B
Shares Out	n/a
EPS (ttm)	-119.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,991
Average Volume	314,721
Open	1,105.00
Previous Close	1,105.00
Day's Range	1,075.00 - 1,105.00
52-Week Range	1,200.00 - 2,500.00
Beta	-0.05
RSI	31.72
Earnings Date	May 8, 2025

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 1,012
• Stock Exchange: Nasdaq Iceland
• Ticker Symbol: ALVO

Financial Performance

In 2024, Alvotech's revenue was $491.98 million, an increase of 426.84% compared to the previous year's $93.38 million. Losses were -$231.86 million, -57.98% less than in 2023.

Financial numbers in USD